Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

1. Esteve-Pastor, M.A.
2. Rivera-Caravaca, J.M.
3. Roldán, V.
4. Sanmartin Fernández, M.
5. Arribas, F.
6. Masjuan, J.
7. Barrios, V.
8. Cosin-Sales, J.
9. Freixa-Pamias, R.
10. Recalde, E.
11. Pérez-Cabeza, A.I.
12. Manuel Vázquez Rodríguez, J.
13. Ràfols Priu, C.
14. Anguita Sánchez, M.
15. Lip, G.Y.H.
16. Marin, F.